Why is there still a lack of diversity in clinical trials? Shelli Pavone: Unfortunately equity and healthcare have ...

John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile.

While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates ...